An Open-Label, Multi-Center, Dose-Escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk

Trial Profile

An Open-Label, Multi-Center, Dose-Escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2015

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions
  • Sponsors Peplin
  • Most Recent Events

    • 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top